

#43  
KP  
2/1/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

de la MONTE *et al.*

Appl. No. 09/964,678

Filed: September 28, 2001

For: **Transgenic Animals and Cell  
Lines for Screening Drugs  
Effective for the Treatment or  
Prevention of Alzheimer's Disease**

Confirmation No. 3649

Art Unit: 1633

Examiner: To be assigned

Atty. Docket: 0609.4370002/RWE/FRC



**Amendment and Submission of Substitute Sequence Listing  
Under 37 C.F.R. § 1.825(a)**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with 37 C.F.R. § 1.825(a), Applicants submit substitute sheets to amend the paper copy of the Sequence Listing.

***In the Specification:***

Please cancel the existing Sequence Listing for the above-identified application, replace it with the substitute Sequence Listing appended hereto, and insert the same at the end of the application.

***Remarks***

In accordance with 37 CFR § 1.825(a), Applicants' Attorney hereby states that the change made in the sequence listing, does not include new matter. The substitute Sequence

09964678-012202